Nanomerics

Nanomerics is a privately held speciality pharmaceutical company and a a world leader in molecular engineered delivery technologies.

[Nanomerics @nanomerics]

Nanomerics wins the United Kingdom King’s Award for Enterprise - Innovation 2024
@TheKingsAwards
https://t.co/BuEzbgANXm

[Virpax® Pharmaceuticals, Inc. (Nasdaq: VRPX) @VirpaxPharma]

We are honored to ring the closing bell on July 24th and recognize the hard work and outstanding contributions from our entire team. We have made tremendous progress in moving our product candidates forward and expect to be in human clinical trials in 2024.

https://t.co/TmJLgmz8Ii
https://t.co/VZjnPqwNy4

#VRPX #pharma #pharmanews #pharmaindustry #painmanagement #CNS

[Virpax® Pharmaceuticals, Inc. (Nasdaq: VRPX) @VirpaxPharma]

We are pleased to have been selected to present our MET platform to the science and technology staff at the Defense Threat Reduction Agency (DTRA), Defense Advanced Research Projects Agency (DARPA) in addition to members of the Army, Navy and other military branches and Federal agencies. https://t.co/JsTuB8JtOW

#VRPX #pharmaceuticals #pharma #pharmaindustry #CNS #pain

[Royal Society of Chemistry @RoySocChem]

Thanks @nanomerics for hosting participants on our #RSCBroadeningHorizons programme, which supports students from Black & minority ethnic backgrounds to launch a #ChemCareer, including Kholil Rahman, a postgraduate student at @OfficialUoM🧵 https://t.co/cfmPR5hTCD

[Nanomerics @nanomerics]

Nanomerics Announces Ocular Molecular Envelope Technology (MET) Patent Granted in Canada
The patent together with others takes protection of Nanomerics' ocular Molecular Envelope Technology (MET) franchise, in Canada, to 2035
https://t.co/X4ZmIzY4xs

[Nanomerics @nanomerics]

Nanomerics Awarded an MHRA Innovation Passport for OC134 https://t.co/pPrvkChIaV

[Virpax® Pharmaceuticals, Inc. (Nasdaq: VRPX) @VirpaxPharma]

We applaud this recent statement by Dr. Robert Califf, FDA Commissioner, about supporting development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.

[Nanomerics @nanomerics]

Nanomerics developed NIH-backed nasal nonaddictive pain prospect clears early test https://t.co/fwBMMQG6Qn

[Nanomerics @nanomerics]

Nanomerics CSO Ijeoma Uchegbu appointed to Wellcome's board @wellcometrust https://t.co/Bl9imPUZAM

[Nanomerics @nanomerics]

Nanomerics announces patents granted in the US, Europe and Japan and two key publications on the ocular use of its Molecular Envelope Technology https://t.co/xKWme9AAL6 @MDPIpharma #DrugDelivery

[Academy of Medical Sciences @acmedsci]

Congratulations to our 50 new Fellows announced today

Find out more about these prominent biomedical and health scientists and see the full list on our website: https://t.co/UNQWWOlwiS

#AMSFellows2021

[Nanomerics @nanomerics]

Nanomerics CSO Prof I F Uchegbu elected a fellow of the Academy of Medical Sciences @acmedsci https://t.co/Rtmll1pnd0

[Nanomerics @nanomerics]

Nanomerics receives double milestone payment from @VirpaxPharma for Envelta™️ and MMS019, an antiviral nasal spray https://t.co/N79Sc4SbjZ.

[Nanomerics @nanomerics]

Nanomerics Molecular Mask MM019 inhibits SARS-CoV-2 replication. Press release update with more details https://t.co/SJN0dRyUxN #COVID19 #molecular_mask

[bioRxiv @biorxivpreprint]

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray https://t.co/wlRK76FVNS #bioRxiv

[Nanomerics @nanomerics]

Original tween about our collaboration with the teams @JagiellonskiUni and @ucl

[bioRxiv @biorxivpreprint]

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray https://t.co/wlRK76FVNS #bioRxiv

[Nanomerics @nanomerics]

Nanomerics Molecular Mask Technology (MMT): SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray https://t.co/umuwBIDYy2

[Nanomerics @nanomerics]

Nanomerics receives pIND guidance from the US FDA for NM134 for the treatment of an undisclosed, potentially sight threatening eye disease. https://t.co/UFYrwspWXv

[Nanomerics @nanomerics]

New paper in @MolPharmJournal: Molecular Envelope Technology - first demonstration of highly concentrated subcutaneous formulations with hyaluronidase coated nanoparticles. Encapsulated CUDC-101 successfully suppresses pancreatic cancer in tumour models. https://t.co/n03NWIMDNL

[Nanomerics @nanomerics]

Excellent statement and practical steps from @The_IoD
https://t.co/jgQnMkvgD7